DK2951297T3 - FACTOR X-MUTANTS - Google Patents

FACTOR X-MUTANTS Download PDF

Info

Publication number
DK2951297T3
DK2951297T3 DK14708609.4T DK14708609T DK2951297T3 DK 2951297 T3 DK2951297 T3 DK 2951297T3 DK 14708609 T DK14708609 T DK 14708609T DK 2951297 T3 DK2951297 T3 DK 2951297T3
Authority
DK
Denmark
Prior art keywords
glu
gly
leu
thr
lys
Prior art date
Application number
DK14708609.4T
Other languages
Danish (da)
English (en)
Inventor
Jean-Luc Plantier
Original Assignee
Laboratoire Français Du Fractionnement Et Des Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Français Du Fractionnement Et Des Biotechnologies filed Critical Laboratoire Français Du Fractionnement Et Des Biotechnologies
Application granted granted Critical
Publication of DK2951297T3 publication Critical patent/DK2951297T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21006Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DK14708609.4T 2013-02-04 2014-02-03 FACTOR X-MUTANTS DK2951297T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1350930A FR3001729B1 (fr) 2013-02-04 2013-02-04 Mutants du facteur x
PCT/FR2014/050191 WO2014118481A1 (fr) 2013-02-04 2014-02-03 Mutants du facteur x

Publications (1)

Publication Number Publication Date
DK2951297T3 true DK2951297T3 (en) 2017-08-28

Family

ID=48083383

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14708609.4T DK2951297T3 (en) 2013-02-04 2014-02-03 FACTOR X-MUTANTS

Country Status (13)

Country Link
US (1) US10364424B2 (OSRAM)
EP (1) EP2951297B1 (OSRAM)
JP (2) JP2016506945A (OSRAM)
KR (1) KR101942619B1 (OSRAM)
CN (1) CN104995297B (OSRAM)
AU (1) AU2014210986A1 (OSRAM)
CA (1) CA2900010A1 (OSRAM)
DK (1) DK2951297T3 (OSRAM)
ES (1) ES2636162T3 (OSRAM)
FR (1) FR3001729B1 (OSRAM)
IL (1) IL239889A0 (OSRAM)
MX (1) MX2015009867A (OSRAM)
WO (1) WO2014118481A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
FR3050992A1 (fr) * 2016-05-06 2017-11-10 Lab Francais Du Fractionnement Mutants du facteur x
EP4299585A3 (en) * 2016-05-13 2024-04-17 The Scripps Research Institute Compositions and methods for anti-thrombotic and hemostatic therapies
FR3077296A1 (fr) * 2018-02-01 2019-08-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Dimeres de variants du facteur x

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
JP2007506416A (ja) * 2003-09-26 2007-03-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 合成ヘパラナーゼ分子及びその使用
DK1781782T3 (da) * 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
EP1728798A1 (en) * 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
US9567382B2 (en) * 2008-04-15 2017-02-14 Genzyme Corporation Methods to produce rod-derived cone viability factor (RdCVF)
KR20110114587A (ko) * 2008-12-19 2011-10-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x

Also Published As

Publication number Publication date
CA2900010A1 (en) 2014-08-07
ES2636162T3 (es) 2017-10-05
KR101942619B1 (ko) 2019-01-25
AU2014210986A1 (en) 2015-07-23
WO2014118481A1 (fr) 2014-08-07
IL239889A0 (en) 2015-08-31
EP2951297A1 (fr) 2015-12-09
CN104995297A (zh) 2015-10-21
CN104995297B (zh) 2018-10-26
JP2019050819A (ja) 2019-04-04
EP2951297B1 (fr) 2017-05-03
US20160145598A1 (en) 2016-05-26
MX2015009867A (es) 2015-10-05
FR3001729A1 (fr) 2014-08-08
JP2016506945A (ja) 2016-03-07
US10364424B2 (en) 2019-07-30
KR20150113205A (ko) 2015-10-07
FR3001729B1 (fr) 2015-03-06

Similar Documents

Publication Publication Date Title
US9249404B2 (en) Coagulation factor X polypeptides with modified activation properties
JP6363600B2 (ja) 修飾第x因子ポリペプチドおよびその使用
US9896676B2 (en) Compositions and methods for modulating hemostasis
US9347051B2 (en) Coagulation factor X polypeptides with modified activation properties
JP5833448B2 (ja) セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
DK2951297T3 (en) FACTOR X-MUTANTS
AU6280700A (en) Factor x analog with an improved ability to be activated
US20150337284A1 (en) Factor ix variants
US20190338269A1 (en) Factor x variants
US20160177286A1 (en) Gla-domainless factor x
Class et al. Patent application title: Serene Protease Derivatives and Uses in the Prevention or the Treatment of Blood Coagulation Disorders Inventors: Olivier Christophe (Le Kremlin Bicetre Cedex, FR) Cecile Denis (Le Kremlin Bicetre Cedex, FR) Ghislaine Cherel (Le Kremlin Bicetre Cedex, FR) Paul Gueguen (Brest Cedex, FR) Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)